Encision (ECIA) 10-K 14 Jun 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2018	May 31, 2018	Sep. 30, 2017
Document and Entity Information
Entity Registrant Name	ENCISION INC
Entity Central Index Key	930,775
Document Type	10-K
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 2,470,513
Entity Common Stock, Shares Outstanding		10,683,355
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Current assets:
Cash and cash equivalents	$ 114,538	$ 45,117
Restricted cash	25,000	50,000
Accounts receivable, net of allowance for doubtful accounts of $20,500 at March 31, 2018 and $33,000 at March 31, 2017	962,639	1,042,281
Inventories, net of reserve for obsolescence of $21,000 at March 31, 2018 and $50,000 at March 31, 2017	1,437,159	1,128,412
Prepaid expenses	74,830	62,290
Total current assets	2,614,166	2,328,100
Equipment:
Furniture, fixtures and equipment, at cost	3,021,968	3,161,687
Accumulated depreciation	(2,673,037)	(2,693,302)
Equipment, net	348,931	468,385
Patents, net of accumulated amortization of $238,571 at March 31, 2018 and $212,345 at March 31, 2017	270,504	253,980
Other assets	18,873	16,450
TOTAL ASSETS	3,252,474	3,066,915
Current liabilities:
Accounts payable	466,418	402,914
Accrued compensation	257,133	267,399
Other accrued liabilities	284,550	248,130
Line of credit	0	275,055
Deferred rent	30,384	30,384
Total current liabilities	1,038,485	1,223,882
Long-term liability:
Deferred rent	10,128	40,512
Total liabilities	1,048,613	1,264,394
Shareholders' equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding	0	0
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 10,683,355 issued and outstanding at March 31, 2018 and 2017	23,817,912	23,752,131
Accumulated (deficit)	(21,614,051)	(21,949,610)
Total shareholders' equity	2,203,861	1,802,521
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 3,252,474	$ 3,066,915

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 20,500	$ 33,000
Inventories, reserve for obsolescence	21,000	50,000
Accumulated amortization	$ 238,571	$ 212,345
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock and additional paid-in capital, shares authorized	100,000,000	100,000,000
Common stock and additional paid-in capital, shares issued	10,683,355	10,683,355
Common stock and additional paid-in capital, shares outstanding	10,683,355	10,683,355

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
NET REVENUE	$ 8,754,279	$ 8,869,599
COST OF REVENUE	3,747,256	4,464,134
GROSS PROFIT	5,007,023	4,405,465
OPERATING EXPENSES:
Sales and marketing	2,311,767	2,511,451
General and administrative	1,457,342	1,455,628
Research and development	842,081	1,126,630
Total operating expenses	4,611,190	5,093,709
OPERATING INCOME (LOSS)	395,833	(688,244)
Interest expense, net	(60,643)	(59,721)
Other income (expense), net	369	18,672
Interest and other income (expense), net	(60,274)	(41,049)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	335,559	(729,293)
Provision for income taxes	0	0
NET INCOME (LOSS)	$ 335,559	$ (729,293)
Net income (loss) per share-basic	$ 0.03	$ (0.07)
Net income (loss) per share-diluted	$ 0.03	$ (0.07)
Weighted average shares-basic	10,683,355	10,677,080
Weighted average shares-diluted	10,707,126	10,677,080

Statements of Shareholders_ Equ

Statements of Shareholders’ Equity - USD ($)	Common Stock and Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance, Shares at Mar. 31, 2016	10,673,225
Beginning Balance, Amount at Mar. 31, 2016	$ 23,682,365	$ (21,220,317)	$ 2,462,048
Net loss		(729,293)	(729,293)
Compensation expense related to equities	$ 69,766		69,766
Common stock issued, Shares	10,130
Ending Balance, Shares at Mar. 31, 2017	10,683,355
Ending Balance, Amount at Mar. 31, 2017	$ 23,752,131	(21,949,610)	1,802,521
Net loss		335,559	335,559
Compensation expense related to equities	$ 65,781		65,781
Ending Balance, Shares at Mar. 31, 2018	10,683,355
Ending Balance, Amount at Mar. 31, 2018	$ 23,817,912	$ (21,614,051)	$ 2,203,861

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income (loss)	$ 335,559	$ (729,293)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	202,895	224,877
Stock-based compensation expense related to stock options	65,781	69,766
(Recovery from) provision for doubtful accounts, net change	(12,500)	24,000
(Recovery from) inventory obsolescence, net change	(29,000)	(360,000)
Change in operating assets and liabilities:
Accounts receivable	92,142	(226,431)
Inventories	(279,747)	962,335
Prepaid expenses and other assets	(14,963)	29,175
Accounts payable	63,504	47,024
Accrued compensation and other accrued liabilities	(4,230)	(18,565)
Net cash provided by operating activities	419,441	22,888
Cash flows from investing activities:
Acquisition of property and equipment	(56,562)	(105,357)
Patent costs	(43,403)	(27,818)
Net cash used in investing activities	(99,965)	(133,175)
Cash flows from financing activities:
Paydowns to credit facility, net change	(275,055)	(112,436)
Change in restricted cash	25,000	(25,000)
Net cash used in financing activities	(250,055)	(137,436)
Net increase (decrease) in cash and cash equivalents	69,421	(247,723)
Cash and cash equivalents, beginning of period	45,117	292,840
Cash and cash equivalents, end of period	114,538	45,117
Supplemental disclosures of cash flow information:
Cash paid during the year for interest	$ 50,643	$ 49,980

Description of Business

Description of Business	12 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. We believe that our patented AEM ® We have an accumulated deficit of $21,614,051 at March 31, 2018. Operating funds have been provided primarily by issuances of our common stock and warrants, the exercise of stock options to purchase our common stock, and by operating profits. Our liquidity has diminished because of prior years’ operating losses, and we may be required to seek additional capital in the future. Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals in the United States.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Use of Estimates in the Preparation of Financial Statements. Cash and Cash Equivalents. Fair Value of Financial Instruments. Concentration of Credit Risk. We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We charge interest on past due accounts on a case-by-case basis. A summary of the activity in our allowance for doubtful accounts is as follows: Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 33,000 $ 9,000 Provision for (recoveries of) estimated losses (10,982 ) 24,352 Write-off of uncollectible accounts (1,518 ) (352 ) Balance, end of year $ 20,500 $ 33,000 The net accounts receivable balance at March 31, 2018 of $962,639 included no more than 7% from any one customer. The net accounts receivable balance at March 31, 2017 of $1,042,281 included no more than 5% from any one customer. Warranty Accrual. Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 20,000 $ 20,000 Provision for estimated warranty claims (10,741 ) 2,482 Claims made (741 ) (2,482 ) Balance, end of year $ 10,000 $ 20,000 Inventories. March 31, 2018 March 31, 2017 Raw materials $ 941,964 $ 857,345 Finished goods 516,195 321,067 Total gross inventories 1,458,159 1,178,412 Less reserve for obsolescence (21,000 ) (50,000 ) Total net inventories $ 1,437,159 $ 1,128,412 A summary of the activity in our inventory reserve for obsolescence is as follows: Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 50,000 $ 410,000 Provision for estimated obsolescence 3,816 104,700 Write-off of obsolete inventory (32,816 ) (464,700 ) Balance, end of year $ 21,000 $ 50,000 Property and Equipment. Long-Lived Assets. Patents. March 31, 2018 March 31, 2017 Patents issued $ 447,430 $ 424,080 Accumulated amortization (233,390 ) (208,479 ) Patents issued, net of accumulated amortization 214,040 215,601 Patent applications 61,645 42,245 Accumulated amortization (5,181 ) (3,866 ) Patent applications, net of accumulated amortization 56,464 38,379 Total net patents and patent applications $ 270,504 $ 253,980 The expected annual amortization expense related to patents and patent applications as of March 31, 2018, for the next five fiscal years, is as follows: Fiscal Year Amount 2019 $ 24,629 2020 24,629 2021 21,712 2022 20,253 2023 and following 179,281 Total $ 270,504 Other Accrued Liabilities. March 31, 2018 March 31, 2017 Bonus $ 108,000 $ –– Warranty 10,000 20,000 Sales commissions 45,068 88,715 Lease normalization 23,939 31,828 Sales and use tax 17,434 16,505 Marketing fees 7,278 8,466 Professional fees 37,500 47,596 Payroll taxes 24,114 24,577 Miscellaneous 11,217 10,443 Total other accrued liabilities $ 284,550 $ 248,130 Income Taxes. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. The cumulative effect of adopting ASC 740 on April 1, 2007 has been recorded net in deferred tax assets, which resulted in no ASC 740 liability on the balance sheet. The total amount of unrecognized tax benefits as of the date of adoption was zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit the Company’s tax returns from fiscal year ended March 31, 1999 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statements of operations. There have been no income tax related interest or penalties assessed or recorded. Because the Company has provided a full valuation allowance on all of its deferred tax assets, the adoption of ASC 740 had no impact on our effective tax rate. Revenue Recognition. Sales Taxes. Research and Development Expenses Advertising Costs. Stock-Based Compensation. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statements of operations. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statements of operations for fiscal years 2018 and 2017 included compensation expense for share-based payment awards granted prior to, but not yet vested as of March 31, 2018, based on the grant date fair value. Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statements of operations for fiscal years 2018 and 2017 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We used the Black-Scholes option-pricing model (“Black-Scholes model”) to determine fair value. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction. Stock-based compensation expense recognized under ASC 718 for fiscal years 2018 and 2017 was $65,781 and $69,766, respectively, which consisted of stock-based compensation expense related to director and employee stock options. Stock-based compensation expense related to director and employee stock options under ASC 718 for fiscal years 2018 and 2017 was allocated as follows: Years Ended March 31, 2018 March 31, 2017 Cost of sales $ 2,157 $ 2,648 Sales and marketing 13,679 12,645 General and administrative 45,513 49,333 Research and development 4,432 5,140 Stock-based compensation expense $ 65,781 $ 69,766 Segment Reporting. Basic and Diluted Income per Common Share. The following table presents the calculation of basic and diluted net income (loss) per share: Years Ended March 31, 2018 March 31, 2017 Net income (loss) $ 335,559 $ (729,293 ) Weighted-average shares — basic 10,683,355 10,677,080 Effect of dilutive potential common shares 23,771 — Weighted-average shares — basic and diluted 10,707,126 10,677,080 Net loss per share — basic and diluted $ 0.03 $ (0.07 ) Antidilutive equity units 983,765 954,286 Recent Accounting Pronouncements. In July 2015, the FASB issued Accounting Standards Update 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, ("ASU 2015-11"). ASU 2015-11 affects reporting entities that measure inventory using first-in, first-out (FIFO) or average cost. Specifically, ASU 2015-11 requires that inventory be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 and it has been adopted. The Company does not expect ASU 2015-11 to have a material/significant impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 will be effective for the Company beginning in its third quarter of 2020 and early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact of adopting the new lease standard on its consolidated financial statements. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company's lease portfolio as of the adoption date.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Stock Option Plans. Under ASC 718, the value of each employee stock option was estimated on the date of grant using the Black-Scholes model for the purpose of financial information in accordance with ASC 718. The use of a Black-Scholes model requires the use of actual employee exercise behavior data and the use of a number of assumptions including expected volatility, risk-free interest rate and expected dividends. Employee stock options for 200,000 and 285,000 shares of stock were granted during fiscal years 2018 and 2017, respectively. As of March 31, 2018, $135,000 of total unrecognized compensation costs related to nonvested stock is expected to be recognized over a period of five years. The assumptions for employee stock options are summarized as follows: Years Ended March 31, 2018 March 31, 2017 Risk-free interest rate 1.8% to 1.9% 1.1% to 1.7% Expected life (in years) 5.0 5.0 Expected volatility 93% to 95% 81% to 87% Expected dividend 0% 0% Cumulative compensation cost recognized in net income or loss with respect to options that are forfeited prior to vesting is adjusted as a reduction of compensation expense in the period of forfeiture. The volatility of the stock is based on the historical volatility for the period that approximates the expected lives of the options being valued. Fair value computations are highly sensitive to the volatility factor; the greater the volatility, the higher the computed fair value of options granted. The total fair value of options granted was computed to be approximately $64,898 and $474,000, for the fiscal years ended March 31, 2018 and 2017, respectively. For disclosure purposes, these amounts are amortized ratably over the vesting periods of the options. Effects of stock-based compensation, net of the effect of forfeitures, totaled $65,781 and $69,766 for fiscal years 2018 and 2017, respectively. The Black-Scholes model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the use of assumptions, including the expected stock price volatility. Because our employee stock options have characteristics significantly different than those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our employee stock options. A summary of our stock option activity and related information for equity compensation plans approved by security holders for each of the fiscal years ended March 31, 2018 and 2017 is as follows: STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2016 411,000 $ 0.85 Granted 285,000 0.31 Forfeited/expired (11,000 ) 0.86 BALANCE AT MARCH 31, 2017 685,000 $ 0.63 Granted 200,000 0.45 Forfeited/expired (126,750 ) 0.75 BALANCE AT MARCH 31, 2018 758,250 $ 0.56 A summary of our stock option activity and related information for equity compensation plans not approved by security holders for the fiscal year ended March 31, 2018 is as follows: STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2016 245,000 $ 0.96 Granted — — Forfeited/expired — — BALANCE AT MARCH 31, 2017 245,000 $ 0.96 Granted — — Forfeited/expired (20,000 ) 1.00 BALANCE AT MARCH 31, 2018 225,000 $ 0.96 The following table summarizes information about employee stock options outstanding and exercisable at March 31, 2018: STOCK OPTIONS OUTSTANDING STOCK OPTIONS EXERCISABLE Range of Exercise Prices Number Outstanding Weighted-Average Remaining Contractual Life (in Years) Weighted-Average Exercise Price per Share Number Exercisable Weighted-Average Exercise Price per Share $0.30 - $0.74 568,250 3.4 $0.42 226,954 $0.43 $0.82 - $1.01 325,000 0.8 $0.87 275,812 $0.87 $1.15 - $1.50 90,000 0.4 $1.26 83,395 $1.26 983,250 2.2 $0.65 586,161 $0.76 A summary of our RSU activity and related information for equity compensation plans approved by security holders for the fiscal year ended March 31, 2018 is as follows: RSUs OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2017 24,286 $ 0.62 Granted — — Forfeited/expired — — BALANCE AT MARCH 31, 2018 24,286 $ 0.62 The 983,250 options outstanding as of March 31, 2018 are nonqualified stock options. The exercise price of all options granted through March 31, 2018 has been equal to or greater than the fair market value, as determined by our Board of Directors or based upon publicly quoted market values of our common stock on the date of the grant. As of March 31, 2018, 62,464 equity units for our common stock remain available for grant under the Plan.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Effective November 9, 2017, we extended our noncancelable lease agreement through July 31, 2024 for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease includes base rent abatement for the first two months, or $55,583, and $145,000 of leasehold improvements granted by the landlord. At the start of the lease on August 1, 2019, the $145,000 will be recorded on our condensed balance sheets as leasehold improvements and deferred rent. The leasehold improvements will be amortized over the lesser of the lease term or the assets life and the deferred rent will be amortized against rent expense over the lease term. The minimum future lease payment, by fiscal year, as of March 31, 2018 is as follows: Fiscal Year Amount 2019 $ 295,365 2020 322,738 2021 343,167 2022 357,667 2023 372,167 2024 386,667 2025 130,500 Total $ 2,208,271 In March 2016, we entered into a loan and security agreement with Crestmark Bank. The loan is due on demand and has no financial covenants. Under the agreement, we were provided with a line of credit that is not to exceed the lesser of $1,000,000 or 85% of eligible accounts receivable. The interest rate is prime rate plus 2%, with a floor of 5.5%, plus a monthly maintenance fee of 0.4%, based on the average monthly loan balance. Interest is charged on a minimum loan balance of $500,000, a loan fee of 1% annually, and an exit fee of 1% during year three. As of March 31, 2018, we had no borrowings from the credit facility and had an additional $561,049 available to borrow. We are subject to regulation by the United States Food and Drug Administration (“FDA”). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine our and their compliance with these regulations. As of March 31, 2018, we believe we were in substantial compliance with all known regulations. FDA inspections are conducted periodically at the discretion of the FDA. We were last inspected in December 2012 and were notified of five observations from that inspection, none of which we believe to be material. Our obligation with respect to employee severance benefits is minimized by the “at will” nature of the employee relationships. Our total obligation with respect to contingent severance benefit obligations was none as of March 31, 2018 and 2017.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	We account for income taxes under ASC 740, which requires the use of the liability method. ASC 740 provides that deferred income tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred income tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred income tax assets and liabilities are expected to be settled or realized. The following is a reconciliation between the effective rate and the federal statutory rate used in determining deferred tax assets: Years Ended March 31, 2018 March 31, 2017 Expected income tax rate $ 103,000 $ (248,000 ) State income taxes, net of federal tax benefit 12,000 (26,000 ) Change in valuation allowance (1,650,000 ) 248,000 Other permanent differences 27,000 26,000 Rate change 1,491,000 –– Other differences 17,000 –– Income tax expense $ –– $ –– The components of the net accumulated deferred income tax asset (liability) are as follows: Years Ended March 31, 2018 March 31, 2017 Other deferred assets $ 45,000 $ 99,000 Valuation allowance (45,000 ) (99,000 ) Current deferred tax assets –– –– Credits and net operating loss carryforwards 3,003,000 4,775,000 Valuation allowance (3,003,000 ) (4,775,000 ) Long-term deferred tax assets –– –– Total deferred tax assets –– –– Valuation allowance –– –– Long-term deferred tax liabilities –– –– Total deferred tax liabilities –– –– Net deferred tax assets (liabilities) $ –– $ –– The primary components of our deferred tax assets are describe below: Years Ended March 31, 2018 March 31, 2017 Differences in reporting long-term assets $ 45,000 $ 99,000 Credits and net operating loss carryforwards 3,003,000 4,775,000 Less valuation allowance (3,048,000 ) (4,874,000 ) Total deferred tax assets $ –– $ –– In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which net operating losses and reversal of timing differences may offset taxable income. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. The reduced deferred tax assets and valuation allowance at March 31, 2018 primarily reflects the impact of complying with the Tax Cuts and Jobs Act of 2017. As of March 31, 2018, we had approximately $11.7 million of net operating loss carryovers for tax purposes. Additionally, we have approximately $239,000 of research and development tax credits available to offset future federal income taxes. The net operating loss and credit carryovers begin to expire in the fiscal year ended March 31, 2019. In the fiscal year ended March 31, 2019, net operating loss of approximately $1,8 million will expire if sufficient taxable income is not available to use it. In fiscal years ended after March 31, 2019, net operating losses expire at various dates through March 31, 2037. Our net operating loss carryovers at March 31, 2018 include $455,000 in income tax deductions related to stock options which will be tax effected and the benefit will be reflected as a credit to additional paid-in capital when realized. As such, these deductions are not reflected in our deferred tax assets. The Internal Revenue Code contains provisions, which may limit the net operating loss carryforwards available to be used in any given year if certain events occur, including significant changes in ownership interests.

Major Customers_Suppliers

Major Customers/Suppliers	12 Months Ended
	Mar. 31, 2018
Major Customers/Suppliers
Major Customers/Suppliers	We depend on sales that are generated from hospitals’ ongoing usage of AEM surgical instruments. In fiscal year 2018, we generated sales from over 300 hospitals that have changed to AEM products, but no hospital customer contributed more than 4% to the total sales. We have a relationship with ATL Technology, LLC who accounted for approximately 23% of our purchases in fiscal year 2018.

Defined Contribution Employee B

Defined Contribution Employee Benefit Plan	12 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Defined Contribution Employee Benefit Plan	We have adopted a 401(k) Profit Sharing Plan which covers all full-time employees who have completed at least three months of full-time continuous service and are age eighteen or older. Participants may defer up to 20% of their gross pay up to a maximum limit determined by law. Participants are immediately vested in their contributions. We may make discretionary contributions based on corporate financial results for the fiscal year. To date, we have not made contributions to the 401(k) Profit Sharing Plan. Vesting in a contribution account (our contribution) is based on years of service, with a participant fully vested after five years of credited service.

Related Party Transaction

Related Party Transaction	12 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transaction	We paid consulting fees of $73,195 and $79,167 to an entity owned by one of our directors in fiscal years 2018 and 2017, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Management evaluated all activity of us and concluded that, as of the date the financial statements were issued, no subsequent events have occurred that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements.
Cash and Cash Equivalents	Cash and Cash Equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments.
Concentration of Credit Risk	Concentration of Credit Risk. We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We charge interest on past due accounts on a case-by-case basis. A summary of the activity in our allowance for doubtful accounts is as follows: Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 33,000 $ 9,000 Provision for (recoveries of) estimated losses (10,982 ) 24,352 Write-off of uncollectible accounts (1,518 ) (352 ) Balance, end of year $ 20,500 $ 33,000 The net accounts receivable balance at March 31, 2018 of $962,639 included no more than 7% from any one customer. The net accounts receivable balance at March 31, 2017 of $1,042,281 included no more than 5% from any one customer.
Warranty Accrual	Warranty Accrual. Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 20,000 $ 20,000 Provision for estimated warranty claims (10,741 ) 2,482 Claims made (741 ) (2,482 ) Balance, end of year $ 10,000 $ 20,000
Inventories	Inventories. March 31, 2018 March 31, 2017 Raw materials $ 941,964 $ 857,345 Finished goods 516,195 321,067 Total gross inventories 1,458,159 1,178,412 Less reserve for obsolescence (21,000 ) (50,000 ) Total net inventories $ 1,437,159 $ 1,128,412 A summary of the activity in our inventory reserve for obsolescence is as follows: Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 50,000 $ 410,000 Provision for estimated obsolescence 3,816 104,700 Write-off of obsolete inventory (32,816 ) (464,700 ) Balance, end of year $ 21,000 $ 50,000
Property and Equipment	Property and Equipment.
Long-Lived Assets	Long-Lived Assets.
Patents	Patents. March 31, 2018 March 31, 2017 Patents issued $ 447,430 $ 424,080 Accumulated amortization (233,390 ) (208,479 ) Patents issued, net of accumulated amortization 214,040 215,601 Patent applications 61,645 42,245 Accumulated amortization (5,181 ) (3,866 ) Patent applications, net of accumulated amortization 56,464 38,379 Total net patents and patent applications $ 270,504 $ 253,980 The expected annual amortization expense related to patents and patent applications as of March 31, 2018, for the next five fiscal years, is as follows: Fiscal Year Amount 2019 $ 24,629 2020 24,629 2021 21,712 2022 20,253 2023 and following 179,281 Total $ 270,504
Other Accrued Liabilities	Other Accrued Liabilities. March 31, 2018 March 31, 2017 Bonus $ 108,000 $ –– Warranty 10,000 20,000 Sales commissions 45,068 88,715 Lease normalization 23,939 31,828 Sales and use tax 17,434 16,505 Marketing fees 7,278 8,466 Professional fees 37,500 47,596 Payroll taxes 24,114 24,577 Miscellaneous 11,217 10,443 Total other accrued liabilities $ 284,550 $ 248,130
Income Taxes	Income Taxes. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. The cumulative effect of adopting ASC 740 on April 1, 2007 has been recorded net in deferred tax assets, which resulted in no ASC 740 liability on the balance sheet. The total amount of unrecognized tax benefits as of the date of adoption was zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit the Company’s tax returns from fiscal year ended March 31, 1999 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statements of operations. There have been no income tax related interest or penalties assessed or recorded. Because the Company has provided a full valuation allowance on all of its deferred tax assets, the adoption of ASC 740 had no impact on our effective tax rate.
Revenue Recognition	Revenue Recognition.
Sales Taxes	Sales Taxes.
Research and Development Expenses	Research and Development Expenses
Advertising Costs	Advertising Costs.
Stock-Based Compensation	Stock-Based Compensation. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statements of operations. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statements of operations for fiscal years 2018 and 2017 included compensation expense for share-based payment awards granted prior to, but not yet vested as of March 31, 2018, based on the grant date fair value. Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statements of operations for fiscal years 2018 and 2017 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We used the Black-Scholes option-pricing model (“Black-Scholes model”) to determine fair value. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction. Stock-based compensation expense recognized under ASC 718 for fiscal years 2018 and 2017 was $65,781 and $69,766, respectively, which consisted of stock-based compensation expense related to director and employee stock options. Stock-based compensation expense related to director and employee stock options under ASC 718 for fiscal years 2018 and 2017 was allocated as follows: Years Ended March 31, 2018 March 31, 2017 Cost of sales $ 2,157 $ 2,648 Sales and marketing 13,679 12,645 General and administrative 45,513 49,333 Research and development 4,432 5,140 Stock-based compensation expense $ 65,781 $ 69,766
Segment Reporting	Segment Reporting.
Basic and Diluted Income per Common Share	Basic and Diluted Income per Common Share. The following table presents the calculation of basic and diluted net income (loss) per share: Years Ended March 31, 2018 March 31, 2017 Net income (loss) $ 335,559 $ (729,293 ) Weighted-average shares — basic 10,683,355 10,677,080 Effect of dilutive potential common shares 23,771 — Weighted-average shares — basic and diluted 10,707,126 10,677,080 Net loss per share — basic and diluted $ 0.03 $ (0.07 ) Antidilutive equity units 983,765 954,286
Recent Accounting Pronouncements	Recent Accounting Pronouncements. In July 2015, the FASB issued Accounting Standards Update 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, ("ASU 2015-11"). ASU 2015-11 affects reporting entities that measure inventory using first-in, first-out (FIFO) or average cost. Specifically, ASU 2015-11 requires that inventory be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 and it has been adopted. The Company does not expect ASU 2015-11 to have a material/significant impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 will be effective for the Company beginning in its third quarter of 2020 and early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact of adopting the new lease standard on its consolidated financial statements. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company's lease portfolio as of the adoption date.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of the activity in allowance for doubtful accounts	Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 33,000 $ 9,000 Provision for (recoveries of) estimated losses (10,982 ) 24,352 Write-off of uncollectible accounts (1,518 ) (352 ) Balance, end of year $ 20,500 $ 33,000
Summary of warranty claims activity, included in other accrued liabilities	Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 20,000 $ 20,000 Provision for estimated warranty claims (10,741 ) 2,482 Claims made (741 ) (2,482 ) Balance, end of year $ 10,000 $ 20,000
Schedule of inventory	March 31, 2018 March 31, 2017 Raw materials $ 941,964 $ 857,345 Finished goods 516,195 321,067 Total gross inventories 1,458,159 1,178,412 Less reserve for obsolescence (21,000 ) (50,000 ) Total net inventories $ 1,437,159 $ 1,128,412
Summary of the activity in inventory reserve for obsolescence	Years Ended March 31, 2018 March 31, 2017 Balance, beginning of year $ 50,000 $ 410,000 Provision for estimated obsolescence 3,816 104,700 Write-off of obsolete inventory (32,816 ) (464,700 ) Balance, end of year $ 21,000 $ 50,000
Summary of patents	March 31, 2018 March 31, 2017 Patents issued $ 447,430 $ 424,080 Accumulated amortization (233,390 ) (208,479 ) Patents issued, net of accumulated amortization 214,040 215,601 Patent applications 61,645 42,245 Accumulated amortization (5,181 ) (3,866 ) Patent applications, net of accumulated amortization 56,464 38,379 Total net patents and patent applications $ 270,504 $ 253,980
Schedule of expected annual amortization expense related to patents and patent applications for the next five fiscal years	Fiscal Year Amount 2019 $ 24,629 2020 24,629 2021 21,712 2022 20,253 2023 and following 179,281 Total $ 270,504
Schedule of other accrued liabilities	March 31, 2018 March 31, 2017 Bonus $ 108,000 $ –– Warranty 10,000 20,000 Sales commissions 45,068 88,715 Lease normalization 23,939 31,828 Sales and use tax 17,434 16,505 Marketing fees 7,278 8,466 Professional fees 37,500 47,596 Payroll taxes 24,114 24,577 Miscellaneous 11,217 10,443 Total other accrued liabilities $ 284,550 $ 248,130
Schedule of stock-based compensation expense related to employee stock options	Years Ended March 31, 2018 March 31, 2017 Cost of sales $ 2,157 $ 2,648 Sales and marketing 13,679 12,645 General and administrative 45,513 49,333 Research and development 4,432 5,140 Stock-based compensation expense $ 65,781 $ 69,766
Schedule of calculation of basic and diluted net income (loss) per share	Years Ended March 31, 2018 March 31, 2017 Net income (loss) $ 335,559 $ (729,293 ) Weighted-average shares — basic 10,683,355 10,677,080 Effect of dilutive potential common shares 23,771 — Weighted-average shares — basic and diluted 10,707,126 10,677,080 Net loss per share — basic and diluted $ 0.03 $ (0.07 ) Antidilutive equity units 983,765 954,286

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2018
Summary of assumptions for employee stock options	Years Ended March 31, 2018 March 31, 2017 Risk-free interest rate 1.8% to 1.9% 1.1% to 1.7% Expected life (in years) 5.0 5.0 Expected volatility 93% to 95% 81% to 87% Expected dividend 0% 0%
Summary of information about employee stock options outstanding and exercisable	STOCK OPTIONS OUTSTANDING STOCK OPTIONS EXERCISABLE Range of Exercise Prices Number Outstanding Weighted-Average Remaining Contractual Life (in Years) Weighted-Average Exercise Price per Share Number Exercisable Weighted-Average Exercise Price per Share $0.30 - $0.74 568,250 3.4 $0.42 226,954 $0.43 $0.82 - $1.01 325,000 0.8 $0.87 275,812 $0.87 $1.15 - $1.50 90,000 0.4 $1.26 83,395 $1.26 983,250 2.2 $0.65 586,161 $0.76
Summary of RSU activity and related information for equity compensation plans	RSUs OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2017 24,286 $ 0.62 Granted — — Forfeited/expired — — BALANCE AT MARCH 31, 2018 24,286 $ 0.62
Equity Compensation Plans Approved [Member]
Summary of stock option activity and related information for equity compensation plans	STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2016 411,000 $ 0.85 Granted 285,000 0.31 Forfeited/expired (11,000 ) 0.86 BALANCE AT MARCH 31, 2017 685,000 $ 0.63 Granted 200,000 0.45 Forfeited/expired (126,750 ) 0.75 BALANCE AT MARCH 31, 2018 758,250 $ 0.56
Equity Compensation Plans Not Approved [Member]
Summary of stock option activity and related information for equity compensation plans	STOCK OPTIONS OUTSTANDING Number Outstanding Weighted-Average Exercise Price per Share BALANCE AT MARCH 31, 2016 245,000 $ 0.96 Granted — — Forfeited/expired — — BALANCE AT MARCH 31, 2017 245,000 $ 0.96 Granted — — Forfeited/expired (20,000 ) 1.00 BALANCE AT MARCH 31, 2018 225,000 $ 0.96

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of minimum future lease payments, by fiscal year	Fiscal Year Amount 2019 $ 295,365 2020 322,738 2021 343,167 2022 357,667 2023 372,167 2024 386,667 2025 130,500 Total $ 2,208,271

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of accounting for the difference between income taxes computed at the federal statutory rate and the provision for income taxes	Years Ended March 31, 2018 March 31, 2017 Expected income tax rate $ 103,000 $ (248,000 ) State income taxes, net of federal tax benefit 12,000 (26,000 ) Change in valuation allowance (1,650,000 ) 248,000 Other permanent differences 27,000 26,000 Rate change 1,491,000 –– Other differences 17,000 –– Income tax expense $ –– $ ––
Schedule of components of the deferred tax asset	The components of the net accumulated deferred income tax asset (liability) are as follows: Years Ended March 31, 2018 March 31, 2017 Other deferred assets $ 45,000 $ 99,000 Valuation allowance (45,000 ) (99,000 ) Current deferred tax assets –– –– Credits and net operating loss carryforwards 3,003,000 4,775,000 Valuation allowance (3,003,000 ) (4,775,000 ) Long-term deferred tax assets –– –– Total deferred tax assets –– –– Valuation allowance –– –– Long-term deferred tax liabilities –– –– Total deferred tax liabilities –– –– Net deferred tax assets (liabilities) $ –– $ –– The primary components of our deferred tax assets are describe below: Years Ended March 31, 2018 March 31, 2017 Differences in reporting long-term assets $ 45,000 $ 99,000 Credits and net operating loss carryforwards 3,003,000 4,775,000 Less valuation allowance (3,048,000 ) (4,874,000 ) Total deferred tax assets $ –– $ ––

Description of Business (Detail

Description of Business (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 21,614,051	$ 21,949,610

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Balance, beginning of year	$ 33,000	$ 9,000
Provision for (recoveries of) estimated losses	(10,982)	24,352
Write-off of uncollectible accounts	(1,518)	(352)
Balance, end of year	$ 20,500	$ 33,000

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Balance, beginning of year	$ 20,000	$ 20,000
Provision for estimated warranty claims	(10,741)	2,482
Claims made	(741)	(2,482)
Balance, end of year	$ 10,000	$ 20,000

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Details 2) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Raw materials	$ 941,964	$ 857,345
Finished goods	516,195	321,067
Total gross inventories	1,458,159	1,178,412
Less reserve for obsolescence	(21,000)	(50,000)
Total net inventories	$ 1,437,159	$ 1,128,412

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details 3) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Balance, beginning of year	$ 50,000	$ 410,000
Provision for estimated obsolescence	3,816	104,700
Write-off of obsolete inventory	(32,816)	(464,700)
Balance, end of year	$ 21,000	$ 50,000

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details 4) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Accumulated amortization	$ (238,571)	$ (212,345)
Total net patents and patent applications	270,504	253,980
Patents [Member]
Patents issued	447,430	424,080
Accumulated amortization	(233,390)	(208,479)
Patents issued, net of accumulated amortization	214,040	215,601
Patent applications	61,645	42,245
Accumulated amortization	(5,181)	(3,866)
Patent applications, net of accumulated amortization	56,464	38,379
Total net patents and patent applications	$ 270,504	$ 253,980

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details 5) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Expected annual amortization expense related to patents and patent applications
2,019	$ 24,629
2,020	24,629
2,021	21,712
2,022	20,253
2023 and following	179,281
Total	$ 270,504	$ 253,980

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details 6) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Bonus	$ 108,000	$ 0
Warranty	10,000	20,000
Sales commissions	45,068	88,715
Lease normalization	23,939	31,828
Sales and use tax	17,434	16,505
Marketing fees	7,278	8,466
Professional fees	37,500	47,596
Payroll taxes	24,114	24,577
Miscellaneous	11,217	10,443
Total other accrued liabilities	$ 284,550	$ 248,130

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 7) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock-based compensation expense related to grants of employee stock options	$ 65,781	$ 69,766
Cost Of Sales [Member]
Stock-based compensation expense related to grants of employee stock options	2,157	2,648
Selling And Marketing Expense [Member]
Stock-based compensation expense related to grants of employee stock options	13,679	12,645
General And Administrative Expense [Member]
Stock-based compensation expense related to grants of employee stock options	45,513	49,333
Research And Development Expense [Member]
Stock-based compensation expense related to grants of employee stock options	$ 4,432	$ 5,140

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details 8) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Net income (loss)	$ 335,559	$ (729,293)
Weighted-average shares - basic	10,683,355	10,677,080
Effect of dilutive potential common shares	23,771
Weighted-average shares - basic and diluted	10,707,126	10,677,080
Net loss per share-basic and diluted	$ 0.03	$ (0.07)
Antidilutive equity units	983,765	954,286

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Accounts receivable	$ 962,639	$ 1,042,281
Depreciation expense	176,016	198,149
Stock based compensation	$ 65,781	$ 69,766

Shareholders' Equity (Details)

Shareholders' Equity (Details)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Equity [Abstract]
Risk-free interest rate, minimum	1.80%	1.10%
Risk-free interest rate, maximum	1.90%	1.70%
Expected life	5 years	5 years
Expected volatility, minimum	93.00%	81.00%
Expected volatility, maximum	95.00%	87.00%
Expected dividend	0.00%	0.00%

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Equity Compensation Plans Approved [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at the beginning of the period	685,000	411,000
Granted	200,000	285,000
Forfeited/expired	(126,750)	(11,000)
Balance at the end of the period	758,250	685,000
Balance at the beginning of the period	$ 0.63	$ 0.85
Granted	0.45	0.31
Forfeited/expired	0.75	0.86
Balance at the end of the period	$ 0.56	$ 0.63
Equity Compensation Plans Not Approved [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at the beginning of the period	245,000	245,000
Granted	0	0
Forfeited/expired	(20,000)	0
Balance at the end of the period	225,000	245,000
Balance at the beginning of the period	$ 0.96	$ 0.96
Granted	0	0
Forfeited/expired	1	0
Balance at the end of the period	$ 0.96	$ 0.96

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - Employee Stock Option [Member]	12 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	983,250
Weighted-Average Remaining Contractual Life	2 years 2 months 12 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.65
Number Exercisable | shares	586,161
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.76
$0.30 To $0.74 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	568,250
Weighted-Average Remaining Contractual Life	3 years 4 months 24 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.42
Number Exercisable | shares	226,954
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.43
$0.82 To $1.01 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	325,000
Weighted-Average Remaining Contractual Life	9 months 18 days
Weighted-Average Exercise Price per Share | $ / shares	$ 0.87
Number Exercisable | shares	275,812
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 0.87
$1.15 To $1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding | shares	90,000
Weighted-Average Remaining Contractual Life	4 months 24 days
Weighted-Average Exercise Price per Share | $ / shares	$ 1.26
Number Exercisable | shares	83,395
Exercisable Weighted-Average Exercise Price per Share | $ / shares	$ 1.26

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3) - Restricted Stock Units R S U [Member]	12 Months Ended
	Mar. 31, 2018$ / sharesshares
Balance at the beginning of the period | shares	24,286
Granted | shares	0
Forfeited/expired | shares	0
Balance at the end of the period | shares	24,286
Balance at the beginning of the period | $ / shares	$ 0.62
Granted | $ / shares	0
Forfeited/expired | $ / shares	0
Balance at the end of the period | $ / shares	$ 0.62

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee stock options granted	200,000	285,000
Unrecognized compensation costs	$ 135,000
Fair value of stock options	64,898	$ 474,000
Stock-based compensation, net of the effect of forfeitures	$ 65,781	$ 69,766
Employee Stock Option [Member]
Nonqualified stock options outstanding	983,250

Commitments and Contingencies37

Commitments and Contingencies (Details)	Mar. 31, 2018USD ($)
Minimum future lease payments, by fiscal year
2,019	$ 295,365
2,020	322,738
2,021	343,167
2,022	357,667
2,023	372,167
2,024	386,667
2,025	130,500
Total	$ 2,208,271

Commitments and Contingencies38

Commitments and Contingencies (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Line of credit	$ 0	$ 275,055
Employee benefit obligation	0	$ 0
Additional current borrowing capacity available to borrow	$ 561,049

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Federal statutory rate	$ 103,000	$ (248,000)
State income taxes, net of federal tax benefit	12,000	(26,000)
Change in valuation allowance	(1,650,000)	248,000
Other permanent differences	27,000	26,000
Rate change	1,491,000	0
Other differences	17,000	0
Income tax expense	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Other deferred assets	$ 45,000	$ 99,000
Valuation allowance	(45,000)	(99,000)
Current deferred tax assets	0	0
Credits and net operating loss carryforwards	3,003,000	4,775,000
Valuation allowance	(3,003,000)	(4,775,000)
Long-term deferred tax assets	0	0
Total deferred tax assets	0	0
Valuation allowance	0	0
Long-term deferred tax liabilities	0	0
Total deferred tax liabilities	0	0
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Differences in reporting long-term assets	$ 45,000	$ 99,000
Credits and net operating loss carryforwards	3,003,000	4,775,000
Less valuation allowance	(3,003,000)	(4,775,000)
Total deferred tax assets	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Mar. 31, 2018USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 11,700,000
Operating loss carryforward expiration	Mar. 31, 2037
Research and development tax credits	$ 239,000

Major Customers_Suppliers (Deta

Major Customers/Suppliers (Details)	12 Months Ended
	Dec. 31, 2018
ATL Technology, LLC
Major Customers and Suppliers [Line Items]
Concentration percentage	23.00%

Related Party Transaction (Deta

Related Party Transaction (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Related Party Transaction [Line Items]
Consulting fees paid	$ 73,195
Director [Member]
Related Party Transaction [Line Items]
Consulting fees paid		$ 79,167